CMMI Demos’ Future Unclear After Trump Revokes Biden’s Drug Pricing EO

By Gabrielle Wanneh, Maaisha Osman / January 22, 2025 at 8:10 PM
Stakeholders are watching to see what President Donald Trump’s revocation of a Biden-era executive order on drug pricing will mean for three CMS innovation Center demonstrations spurred by the EO, but which for now appear to be continuing. Biden’s CMS announced in 2023 its intention to test three models: The Medicare $2 Drug List, the Cell and Gene Therapy (CGT) Access model, and the Accelerating Clinical Evidence (ACE) model. The Innovation Center has made progress on the first two models,...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.